Profund Advisors
DAWN icon

Profund Advisors’s Day One Biopharmaceuticals DAWN Stock Holding History

Profund Advisors’s Portfolio DAWN Stock Details DAWN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-27,210
Closed -$583K – 1202
2026
Q1 		$583K Sell
27,210
-30,919
-53% -$436K 0.02% 499
2025
Q4 		$542K Buy
58,129
+30,494
+110% +$255K 0.02% 534
2025
Q3 		$195K Buy
27,635
+6,685
+32% +$46K 0.01% 991
2025
Q2 		$136K Sell
20,950
-3,653
-15% -$25.1K ﹤0.01% 948
2025
Q1 		$195K Sell
24,603
-5,821
-19% -$62.7K 0.01% 912
2024
Q4 		$385K Buy
30,424
+3,533
+13% +$49.2K 0.01% 645
2024
Q3 		$375K Sell
26,891
-716
-3% -$10.2K 0.01% 676
2024
Q2 		$380K Sell
27,607
-3,005
-10% -$44K 0.01% 590
2024
Q1 		$506K Sell
30,612
-8,205
-21% -$123K 0.02% 573
2023
Q4 		$567K Sell
38,817
-1,428
-4% -$17.3K 0.02% 477
2023
Q3 		$494K Sell
40,245
-12,387
-24% -$162K 0.03% 472
2023
Q2 		$628K Buy
52,632
+17,303
+49% +$226K 0.03% 433
2023
Q1 		$472K Buy
+35,329
New +$690K 0.03% 518

Other funds holding DAWN

IFP Advisors
IFP Advisors Tampa, Florida $5.86B AUM 20.09% 1-Year Est. Return

Profund Advisors's DAWN Position: Q2 2026 in Review

Profund Advisors sold out of Day One Biopharmaceuticals (DAWN) in Q2 2026, closing a stake of 27,210 shares — an estimated $583K sold.

Profund Advisors first reported a position in DAWN in Q1 2023 and held it in 13 quarters. The position peaked at $628K in Q2 2023. 1 fund tracked by Wall St. Rank holds DAWN as of Q2 2026.

  • Profund Advisors reported no remaining Day One Biopharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Profund Advisors sold 27,210 Day One Biopharmaceuticals shares in Q2 2026, an estimated $583K.
  • Profund Advisors first reported a position in Day One Biopharmaceuticals in Q1 2023 and held it in 13 quarters.
  • Profund Advisors's Day One Biopharmaceuticals position peaked at $628K in Q2 2023.
  • 1 fund tracked by Wall St. Rank held Day One Biopharmaceuticals as of Q2 2026.

Based on Profund Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.